Benefits of pharmacist clinic offset costs by 6-fold

1998 ◽  
Vol 185 (1) ◽  
pp. 6-6
Keyword(s):  
Pharmacist Clinic

Towards OPtimising Care of Regionally-Based Cardiac Patients With a Telehealth Cardiology Pharmacist Clinic (TOPCare Cardiology)

2021 ◽  
Author(s):  
Adam C. Livori ◽  
Jaclyn L. Bishop ◽  
Sophie E. Ping ◽  
Ernesto Oqueli ◽  
Rosemary Aldrich ◽  
...  
Keyword(s):  
Cardiac Patients ◽  
Pharmacist Clinic

Polypharmacy and potentially inappropriate medication use is highly prevalent in multiple myeloma patients and is improved by a collaborative physician–pharmacist clinic

2019 ◽  
Vol 26 (3) ◽  
pp. 536-542 ◽  
Author(s):  
Karen Sweiss ◽  
Gregory S Calip ◽  
Scott Wirth ◽  
Damiano Rondelli ◽  
Pritesh Patel
Keyword(s):  
Multiple Myeloma ◽  
Confidence Interval ◽  
Lower Risk ◽  
Inappropriate Medication ◽  
Medication Use ◽  
High Rate ◽  
Potentially Inappropriate Medication ◽  
Cancer Center ◽  
Inappropriate Medication Use ◽  
Pharmacist Clinic

Objective To compare polypharmacy and potentially inappropriate medication use in multiple myeloma patients receiving care under a traditional, physician-managed, or collaborative physician–pharmacist clinic. Design Retrospective chart review. Setting Urban academic cancer center. Data source Computerized electronic record. Patients Forty-four patients in the traditional physician-managed clinic and 57 patients in the collaborative physician-pharmacist clinic. Measurements and main results Patients in the collaborative clinic took fewer medications on average (9 vs. 7, p = 0.045). Although the median number of myeloma-related medications was higher (2 vs. 4, p < 0.0001), the number of non-myeloma-related medications was lower (7 vs. 3, p < 0.0001) in the collaborative clinic. Polypharmacy rates were high in both clinics (93% vs. 84%, p = 0.22). However, the collaborative clinic had a lower rate of polypharmacy of non-myeloma medications (71 vs. 33%, p = 0.0003), including both minor (five to nine medications, 48 vs. 28%, p = 0.06) and major (≥10 medications, 23 vs. 5%, p = 0.02) polypharmacy. Minor polypharmacy of myeloma-related medications was higher in the collaborative clinic (32 vs. 2%; p = 0.0002). Multivariate analysis showed a reduced risk of having a higher number of medications (Relative risk (RR) 0.79, 95% confidence interval 0.67–0.93; p = 0.004), a lower risk of having any polypharmacy of non-myeloma-related medications (RR 0.41, 95% confidence interval 0.25–0.67; p < 0.001) and a lower risk of receiving potentially inappropriate medication (RR 0.62, 95% confidence interval 0.41–0.95; p = 0.029) in the collaborative clinic. Conclusions Multiple myeloma patients have a high rate of polypharmacy but comanagement with a pharmacist reduced the number of all medications, but in particular the number of non-myeloma-related medications.

scholarly journals Initiatives for immune-related adverse events by the outpatient pharmacist clinic

2022 ◽  
Vol 6 (1) ◽  
pp. 3
Author(s):  
Kiyonori Hamatake ◽  
Kazuaki Kojima
Keyword(s):  
Early Detection ◽  
Adverse Events ◽  
Immune Checkpoint Inhibitor ◽  
Late Onset ◽  
Onset Time ◽  
Care Practice ◽  
Post Marketing Surveillance ◽  
Post Marketing ◽  
Detection Ratio ◽  
Pharmacist Clinic

Early detection is the key in managing side effects because immune-related adverse events (irAEs) are becoming more serious, and their onset time differs. In our hospital, we conducted an outpatient pharmacist clinic for early detection of irAEs by self-care practice for the cases of immune checkpoint inhibitor administration. As a result of a retrospective survey of 207 cases, the percentage of irAEs found by pharmacist’s suggestion of the outpatient pharmacist clinic increased over time, and a high detection ratio was obtained even for irAEs with a late onset time. The incidence of serious irAEs was higher than that in the immediate post-marketing surveillance, and different factors were considered. Although there were some problems, the outpatient pharmacist clinic had a certain effect.

Outcome Benefits Seen With 1 Year of Optimized Sacubitril/Valsartan for the Treatment of Systolic Heart Failure Managed by Pharmacists in a Cardiology Practice

2021 ◽  
pp. 106002802110361
Author(s):  
Lindsay E. Davis ◽  
Elizabeth K. Pogge
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Secondary Outcome ◽  
First Year ◽  
Ventricular Ejection Fraction ◽  
Neprilysin Inhibitor ◽  
The Impact ◽  
Pharmacist Clinic

Background: Pharmacists’ care in heart failure (HF) management has been shown to better clinical outcomes, including use of guideline-directed medical therapy and hospital readmission, although the impact observed has varied among studies. Objective: To investigate the rates of all-cause hospitalization and hospitalization from HF (hHF) and changes in surrogate markers (left-ventricular ejection fraction, New York Heart Association Functional Classification [NYHA FC], diuretic requirements) for patients with HF with reduced ejection fraction (HFrEF) on angiotensin receptor-neprilysin inhibitor (ARNi) therapy optimized within a pharmacist clinic. Methods: Retrospective chart review of patients with HFrEF on sacubitril/valsartan from July 7, 2015, through January 1, 2018. Results: For the primary outcome analysis, 70 patients with pre/post hospitalization data had a reduction in the rate of all-cause hospitalization from 45.7% in the 12 months prior to ARNi therapy initiation to 24.3% during the first year on optimized ARNi therapy ( P = 0.004). The rate of hHF reduced from 24.3% to 8.6% ( P = 0.003). For the secondary outcome analyses at the 6-month assessment point, which included 104 patients, ejection fraction improved from 26% to 34% ( P < 0.001), NYHA FC improved or remained unchanged in 86.6% of patients, and weekly loop diuretic dosing requirements were significantly reduced. Conclusion and Relevance: Real-world use of sacubitril/valsartan optimized within a pharmacist clinic was associated with reduced prevalence of all-cause and hHF during the first year of ARNi therapy. This study corroborates pharmacist involvement in HF management, which could be used to support further research and expanded pharmacist services.

scholarly journals O31 Value for money: a biologic pharmacist clinic

Rheumatology ◽  
2018 ◽  
Vol 57 (suppl_3) ◽  
Author(s):  
Amit Sahni ◽  
Philip Kirkpatrick ◽  
Mark Lloyd
Keyword(s):  
Value For Money ◽  
Pharmacist Clinic
Sign in / Sign up

Export Citation Format

Share Document